Walking Performances and WOMAC Score
Meriva® was evaluated for its efficacy in 50 individuals affected by bone health challenge (X-ray diagnosis confirmation).(1)
The symptoms were evaluated by the WOMAC score; mobility was studied by walking performance on the treadmill and the overall inflammatory response function was assessed by measurements of C-reactive protein plasma concentration.
The trial was conducted over a three months’ period, and the individuals were randomly divided into two groups receiving respectively Meriva® 1 g/die (in two separate administrations) and the “best available treatment”, or the “best available treatment” alone, as defined by the individuals’ general practitioners or specialists. The treadmill performance (10% inclination, 3 Km/h speed) showed an improvement of 201% of the initial walked distance at two months, and a further improvement (+44%) at three months from the beginning of the study. These positive results were complemented by secondary end-points, namely the decrease in supplemental therapy use (63% in the Meriva® group vs 12% in the treatment group) and the decrease in gastrointestinal complications (38% in Meriva® vs 15% in controls (p<0.05).
Overall, the management costs in the Meriva® group decreased by 49% compared to a non significant 3% decrease for the control group.
In a second study(2), the activity of Meriva® for the maintenance of bone health was further confirmed in a larger and longer (8 months) investigation, that enrolled 100 participants and was, otherwise, methodologically similar to the previous one, including the dosage (1 g/day of Meriva®, corresponding to 200 mg curcumin/day in two separate administrations).
The results showed that the Meriva® group enjoyed a statistically significant reduction in all primary clinical endpoints, the Western Ontario and McMaster Universities (WOMAC) score (decreased from 80.6 to 33.2), the Karnofsky Performance Scale (improved from 73.3 to 92.2), and the treadmill walking performance test. These results were complemented by the evaluation of a series of inflammatory response function markers wider than the one considered in the first study (interleukin [IL]-1b, IL-6, soluble CD40 ligand [sCD40L], soluble vascular cell adhesion molecule (sVCAM)-1, and erythrocyte sedimentation rate [ESR]) that also showed a marked reduction in the Meriva® treated group. Conversely, no significant variation was observed in the “best available treatment” control group.
(1) Belcaro G., Cesarone M.R., Dugall M., Pellegrini L., Ledda A., Grossi M.G., Togni S., Appendino G., Panminerva Medica, 2010, 52(2 Suppl 1): p. 55-62.
(2) Belcaro G., Cesarone M.R., Dugall M. et al., Altern Med Rev, 2010, 15(4): p. 337-44